Clinical trial · Interventional
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma: Pilot Study
NCT05422521CI-TRIAL-00115068CART-OmiccompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory non-Hodgkin's lymphoma or in relapse.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory or Relapsed Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood samples and 18FDG PET-CT exams | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- identification of predictive and prognostic biomarkers
- interventionNames
- Other: blood samples and 18FDG PET-CT exams
Primary outcomes (1)
- measure
- Progression-free survival (PFS) compared and correlated with signatures of the radiomics and serum metabolomics index
- timeFrame
- 7 days, 1 month, 3 months, 6 months, 9 months and 12 months post treatment.
- description
- Progression-free survival (PFS)
Secondary outcomes (1)
- measure
- Occurrence of severe side effects compared and correlated with the signatures of the radiomics and serum metabolomics indexes.
- timeFrame
- 7 days, 1 month, 3 months, 6 months, 9 months and 12 months after injection
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than or equal to 18 years old * Patients with histologically proven, refractory or relapsed, non-Hodgkin's lymphoma as indicated for CAR T-cell therapy * ECOG score 0 to 2 * Affiliated patient or beneficiary of a social security scheme * Patient having signed prior informed consent. Exclusion Criteria: * Be under 18 years old, * Contraindication to performing 18FDG PET-CT examinations: severe claustrophobia, unbalanced diabetes during PET-CT examinations (young capillary blood sugar ≥ 11 mmol), * Any participation in other biomedical studies relating to drugs, medical devices or imaging techniques is prohibited, with the exception of so-called non-health product biomedical studies. * Hypersensitivity to the active substance or to any of the excipients in the composition of CAR T-cells preparations * Pregnant or breastfeeding women
References
Publications (0)
Data not yet available
No reference posted for this study.